DE69115711D1 - Verfahren zur arzneiformulierung sowie arzneimittel - Google Patents

Verfahren zur arzneiformulierung sowie arzneimittel

Info

Publication number
DE69115711D1
DE69115711D1 DE69115711T DE69115711T DE69115711D1 DE 69115711 D1 DE69115711 D1 DE 69115711D1 DE 69115711 T DE69115711 T DE 69115711T DE 69115711 T DE69115711 T DE 69115711T DE 69115711 D1 DE69115711 D1 DE 69115711D1
Authority
DE
Germany
Prior art keywords
pellets
pct
dosage
cohesive
date apr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69115711T
Other languages
English (en)
Other versions
DE69115711T2 (de
Inventor
Arne Kristensen
Per Holm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of DE69115711D1 publication Critical patent/DE69115711D1/de
Application granted granted Critical
Publication of DE69115711T2 publication Critical patent/DE69115711T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69115711T 1990-10-16 1991-10-15 Verfahren zur arzneiformulierung sowie arzneimittel Expired - Fee Related DE69115711T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003296A SE9003296L (sv) 1990-10-16 1990-10-16 Foerfarande foer att formulera laekemedel
PCT/SE1991/000690 WO1992006679A1 (en) 1990-10-16 1991-10-15 A method for drug formulation and a pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69115711D1 true DE69115711D1 (de) 1996-02-01
DE69115711T2 DE69115711T2 (de) 1996-05-30

Family

ID=20380654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69115711T Expired - Fee Related DE69115711T2 (de) 1990-10-16 1991-10-15 Verfahren zur arzneiformulierung sowie arzneimittel

Country Status (14)

Country Link
US (1) US5476667A (de)
EP (1) EP0553169B1 (de)
JP (1) JP3459011B2 (de)
AT (1) ATE131727T1 (de)
AU (1) AU650683B2 (de)
CA (1) CA2094030C (de)
DE (1) DE69115711T2 (de)
DK (1) DK0553169T3 (de)
ES (1) ES2081498T3 (de)
GR (1) GR3019360T3 (de)
IE (1) IE74194B1 (de)
PT (1) PT99245B (de)
SE (1) SE9003296L (de)
WO (1) WO1992006679A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
WO1995009044A1 (en) * 1993-09-29 1995-04-06 E.I. Du Pont De Nemours And Company Melt granulation with dielectric heating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
ES2168290T3 (es) * 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
EP0672416A1 (de) * 1994-03-14 1995-09-20 Euro-Celtique S.A. Diamorphin enthaltendes Arzneimittel
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
GB9422154D0 (en) † 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
WO2000044353A1 (de) 1999-01-29 2000-08-03 Losan Pharma Gmbh Pharmazeutische zusammensetzungen
US6248718B1 (en) 1999-08-18 2001-06-19 Atlantic Biomed Corporation Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
FR2816507B1 (fr) * 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
DE10300325A1 (de) 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
WO2005000237A2 (en) * 2003-06-25 2005-01-06 University Of Tennessee Research Foundation Granules containing biologically active substances
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1972335A1 (de) * 2007-03-23 2008-09-24 Krka Feste Dosierungsformen mit Aliskiren und pharmazeutisch zulässigen Salzen davon
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090110716A1 (en) 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US8807979B2 (en) * 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
DE102012007671A1 (de) 2012-04-16 2013-10-17 Acino Pharma Ag Pellets mit hohem Wirkstoffgehalt
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
FR3014317B1 (fr) 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
RU2712267C2 (ru) 2014-01-10 2020-01-28 Джонсон энд Джонсон Консьюмер Инк. Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
DE2360796B2 (de) * 1973-12-06 1977-06-02 Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm
US4129666A (en) * 1977-04-29 1978-12-12 Walter Wizerkaniuk Method of providing pellets with a water insoluble coating using a melt
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
IT1180507B (it) * 1984-06-29 1987-09-23 Roberto Valducci Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten

Also Published As

Publication number Publication date
PT99245B (pt) 1999-04-30
SE9003296L (sv) 1992-04-17
JPH06502151A (ja) 1994-03-10
CA2094030A1 (en) 1992-04-17
IE913627A1 (en) 1992-04-22
WO1992006679A1 (en) 1992-04-30
AU8745991A (en) 1992-05-20
ES2081498T3 (es) 1996-03-16
CA2094030C (en) 2003-06-17
DK0553169T3 (da) 1996-05-13
EP0553169A1 (de) 1993-08-04
SE9003296D0 (sv) 1990-10-16
AU650683B2 (en) 1994-06-30
ATE131727T1 (de) 1996-01-15
US5476667A (en) 1995-12-19
DE69115711T2 (de) 1996-05-30
IE74194B1 (en) 1997-07-16
PT99245A (pt) 1992-09-30
EP0553169B1 (de) 1995-12-20
JP3459011B2 (ja) 2003-10-20
GR3019360T3 (en) 1996-06-30

Similar Documents

Publication Publication Date Title
DE69115711D1 (de) Verfahren zur arzneiformulierung sowie arzneimittel
HU9402007D0 (en) Retarde pharmaceutical compositions and process for producing them
HK1033263A1 (en) Pharmaceutical compositions capable of being gelled
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
SE9200858L (sv) Metod för framställning av pellets med fördröjd frisättning
DE69509671D1 (de) Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung
ES8501978A1 (es) Un procedimiento para preparar un agente anti-inflamatorio
DE3877764T2 (de) Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren.
AU1211992A (en) Low dose dry pharmaceutical preparations
FR2698788B1 (fr) Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
AU591258B2 (en) Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
AU1729297A (en) Solid formulations containing trehalose
EP0279149A3 (en) Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same
GB899668A (en) Improvements in or relating to antibiotics

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee